CSL Behring
Clinical trials sponsored by CSL Behring, explained in plain language.
Now part of
CSL Limited
CSL
ASX
Makes plasma-derived and recombinant therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for hemophilia a: experimental clotting factor shows promise in chinese trial Results expected Oct 2026 (estimated)
- New blood clotting drug could cut transfusions in heart surgery Results expected Apr 2027 (estimated)
- New drug aims to calm inflammation in kidney dialysis patients Results expected Aug 2027 (estimated)
- New clotting drug may cut bleeding risk in rare cancer surgery Results expected Sep 2027 (estimated)